Stay updated on Pembrolizumab in Recurrent HNSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent HNSCC Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent HNSCC Clinical Trial page
- Check6 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdds the disease topic 'Squamous cell carcinoma of the head and neck' and a Resources section linking to the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check34 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0, with no visible changes to study details, eligibility criteria, endpoints, or locations.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision: v3.4.2 is now listed, replacing the previous v3.4.1. The site-wide notice about government operating status has been removed.SummaryDifference0.4%

- Check77 days agoChange DetectedA site-wide funding status notice was added, and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Recurrent HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent HNSCC Clinical Trial page.